Labcorp Holdings Inc. $LH Shares Sold by Bartlett & CO. Wealth Management LLC

Bartlett & CO. Wealth Management LLC trimmed its position in Labcorp Holdings Inc. (NYSE:LH) by 1.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 203,823 shares of the medical research company’s stock after selling 3,138 shares during the period. Bartlett & CO. Wealth Management LLC’s holdings in Labcorp were worth $51,569,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. JPL Wealth Management LLC acquired a new position in shares of Labcorp in the third quarter valued at approximately $28,000. Thurston Springer Miller Herd & Titak Inc. acquired a new stake in Labcorp during the fourth quarter worth approximately $26,000. Hilton Head Capital Partners LLC acquired a new stake in Labcorp during the fourth quarter worth approximately $27,000. Eagle Bay Advisors LLC purchased a new stake in Labcorp in the 4th quarter worth approximately $29,000. Finally, DV Equities LLC purchased a new stake in Labcorp in the 4th quarter worth approximately $29,000. 95.94% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on LH shares. Evercore reissued an “outperform” rating and set a $300.00 price target on shares of Labcorp in a research note on Wednesday, April 8th. Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Labcorp in a research report on Friday, May 8th. Bank of America upped their target price on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research report on Sunday, July 12th. Finally, Robert W. Baird raised their price target on Labcorp from $335.00 to $338.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Nine equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $314.40.

Labcorp Stock Performance

Shares of LH stock opened at $283.63 on Friday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.54 and a current ratio of 1.73. The firm has a market capitalization of $23.26 billion, a price-to-earnings ratio of 25.12, a price-to-earnings-growth ratio of 1.87 and a beta of 0.89. Labcorp Holdings Inc. has a one year low of $241.81 and a one year high of $293.72. The company has a 50 day moving average price of $266.22 and a 200 day moving average price of $267.91.

Labcorp (NYSE:LH) last announced its quarterly earnings results on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, beating analysts’ consensus estimates of $4.09 by $0.16. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The company had revenue of $3.54 billion for the quarter, compared to analyst estimates of $3.51 billion. During the same quarter last year, the business earned $3.84 EPS. Labcorp’s revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Sell-side analysts anticipate that Labcorp Holdings Inc. will post 18 EPS for the current year.

Labcorp Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be issued a $0.72 dividend. The ex-dividend date is Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a yield of 1.0%. Labcorp’s dividend payout ratio (DPR) is presently 25.51%.

Insider Activity at Labcorp

In other news, EVP Kathryn W. Kyle sold 762 shares of the firm’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $263.89, for a total value of $201,084.18. Following the transaction, the executive vice president directly owned 3,813 shares in the company, valued at $1,006,212.57. This trade represents a 16.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 5,903 shares of Labcorp stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $254.50, for a total value of $1,502,313.50. Following the completion of the transaction, the chief executive officer directly owned 107,234 shares in the company, valued at $27,291,053. This represents a 5.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders have sold 6,991 shares of company stock worth $1,796,696. 0.84% of the stock is owned by insiders.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.